Por qué usar preferentemente stents no farmacoactivos

Manuel Gómez Recio; Rosa Lázaro García

Autores/as

Manuel Gómez Recio
Rosa Lázaro García

Resumen

Por qué usar preferentemente stents no farmacoactivos

Descargas

Los datos de descargas todavía no están disponibles.

Citas

1. Díaz JF, de La Torre JM, Sabaté M, Goicolea J. Registro español de Hemodinámica y Cardiología Intervencionista. XXI Informe Oficial de la Sección de Hemodinámica y Cardiología Intervencionista de la Sociedad Española de Cardiología (1990-2011). Rev Esp Cardiol. 2012;65:1106-16.

2. Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in sweden. N Engl J Med. 2007;356(10):1009-19.

3. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent. Circulation. 2004;109(6):701-5.

4. Drug-eluting stents for the treatment of coronary artery disease. NICE technology appraisal guidance 152. Part review of NICE technology appraisal guidance 71. Review date: April 2009. [Artículo en Internet]. 2009. [citado 01 mar 2013]; Disponible en: http://www.nice.org.uk/nicemedia/pdf/TA152Guidance.pdf

5. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of asirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346(23):1773-80.

6. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367(25):2375-84.

7. Stefanini GG, Holmes DR. Drug-eluting coronary-artery stents. N Engl J Med. 2013; 368(3):254-65.

8. Kalesan B, Pilgrim T, Heinimann K, Räber L, Stefanini GG, Valgimigli M, et al. Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33(8):977-87.

9. Kelbaek H, Engstrøm T, Ahtarovski, Lønborg J, Vejlstrup N, Pedersen F, et al. Deferred stent implantation in patients with ST-segment elevation myocardial infarction: a pilot study. EuroIntervention. 2013;8(10):1126-33.

10. Escaned J, Echavarría-Pinto M, Gorgadze T, Gonzalo N, Armengol F, Hernández R, et al. Safety of lone thrombus aspiration without concomitant coronary stenting in selected patients with acute myocardial infarction. EuroIntervention. 2013;8(10):1149-56.

11. Costa JR, Abizaid A, Dudek D, Silber S, Leon MB, Stone GW. Rationale and design of the MGuard for acute ST elevation reperfusion (MASTER) Trial. 2013 ;82(2):184-90.

12. Sarno G, Lagerqvist B, Fröbert O, Nilsson J, Olivecrona G, Omerovic E, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation’ drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J. 2012;33(5):606-13.

13. Fröbert O, Sarno G, James SK, Saleh N, Lagerqvist B. Effect of stent inflation pressure and post-dilatation on the outcome of coronary artery intervention. A Report of more than 90.000 stent implantations. PLoS ONE. 2013;8(2):e56348.